CLINICAL TRIAL: GROWTH HORMONE FEEDBACK IN PATIENTS WITH ACROMEGALY, TYPE 2 DIAB

临床试验：2 型 DIAB 肢端肥大症患者的生长激素反馈

• 批准号: 8174443
• 负责人: John David Carmichael
• 金额: $ 0.37万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8174443
• 关键词: Acromegaly; Attenuated; Binding Proteins; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Evaluation; Failure; Feedback; Funding; Glucose; Grant; Human; Hypothalamic Hormones; Institution; Insulin; Insulin-Like Growth Factor I; Intervention; Measures; Mediating; Non-Insulin-Dependent Diabetes Mellitus; OGTT; Participant; Patients; Peripheral; Placebos; Recombinants; Recruitment Activity; Research; Research Personnel; Resources; Screening procedure; Somatostatin; Somatotropin; Somatotropin-Releasing Hormone; Source; Subcutaneous Injections; United States National Institutes of Health; Visit; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Growth hormone (GH) and Insulin-like growth factor-I (IGF-I) secretion are altered in acromegaly and type 2 DM. The secretion of GH is mediated by central hypothalamic hormones (GH Releasing Hormone and somatostatin) as well as peripheral factors providing feedback inhibition (IGF-I and glucose, among others). The purpose of this study is to compare growth hormone suppression after an oral glucose tolerance test (OGTT) to growth hormone suppression after recombinant human IGF-I (rhIGF-I) administration. This study will recruit participants with active acromegaly, type 2 diabetes mellitus, and healthy control subjects. Each participant will undergo a screening evaluation, and three subsequent visits. Each participant will receive a placebo subcutaneous injection, OGTT, and administration of rhIGF-I, on separate visit days. Glucose, insulin, GH, bioactive IGF-I and IGF-I binding proteins will be measured after each intervention. Results will be compared between the three groups. It is predicted that the administration of rhIGF-I will demonstrate GH suppression in all healthy subjects and subjects with type 2DM. Some acromegaly subjects may demonstrate GH suppression in response to IGF-I administration, but not to the degree seen in healthy subjects or type 2 DM. OGTT will demonstrate suppression of GH in normal subjects, and will show attenuated suppression in type 2 DM and a failure of suppression in acromegaly.

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 生长激素（GH）和胰岛素样生长因子-I（IGF-I）的分泌在肢端肥大症和2型糖尿病中改变。 GH的分泌由中枢下丘脑激素（GH释放激素和生长抑素）以及提供反馈抑制的外周因子（IGF-I和葡萄糖等）介导。 本研究的目的是比较口服葡萄糖耐量试验（OGTT）后的生长激素抑制和重组人IGF-I（rhIGF-I）给药后的生长激素抑制。 本研究将招募患有活动性肢端肥大症、2型糖尿病的受试者和健康对照受试者。 每位参与者将接受筛选评估和三次后续访问。每名受试者将在不同的访视日接受安慰剂皮下注射、OGTT和rhIGF-I给药。 在每次干预后测量葡萄糖、胰岛素、GH、生物活性IGF-I和IGF-I结合蛋白。将比较三组之间的结果。 预计rhIGF-I给药将在所有健康受试者和2型DM受试者中显示GH抑制。 一些肢端肥大症受试者可能对IGF-I给药表现出GH抑制，但未达到健康受试者或2型DM中观察到的程度。 OGTT将显示正常受试者的GH抑制，2型DM的抑制减弱，肢端肥大症的抑制失败。